Lupus & antiphospholipid syndrome
Clinical significance of anti-Ro and Anti-La antibodies: The role of isolated anti-La
Authors' conclusion
The study suggests that patients with isolated anti-La/SSB antibodies may have a unique clinical profile, with a potential protective effect against lupus nephritis but an increased likelihood of cardiac manifestations.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) (≥4 ACR-1997 criteria) in the RELESSER registry3,893 tested for antibodies
- Participants
- 4,219 patients
- Exposure
- Isolated anti-La/SSB positive vs the rest of the SLE patients
- Anti-Ro-/La +n = 44
- Outcome
- Prevalence of isolated anti-La/SSB antibodies
Methodological detailsregistry-based (RELESSER), multivariable regression model
- Registry-based (RELESSER)
- Multivariable regression model
Main finding
As reported in the abstract
Anti-Ro-/La +
1.1%
44 events
Observational data: associations, not effects.
Further findings
Characteristics of isolated anti-La/SSB positive patients: mean age, female, Caucasian
- Mean age (years)
- 33.77
- Female
- 88.6%
- Caucasian
- 90.5%
Most frequent comorbidities: smoking, dyslipidemia, arterial hypertension
- Smoking
- 48.8%
- Dyslipidemia
- 47.7%
- Arterial hypertension
- 31.8%
Photosensitivity and mucosal ulcers
- More common in anti-Ro+/La + patients compared to anti-Ro+/La- and anti-Ro-/La- patients
LN
- Anti-Ro+/La + patients had a lower frequency of LN compared to anti-Ro+/La- patients
Original publication
Clinical significance of anti-Ro and Anti-La antibodies: The role of isolated anti-La. Lupus. Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →